Latest News
AbbVie Inc.
- AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
- AbbVie races into F1 as pharma companies continue push into sport
- McLaren Racing announces partnership with AbbVie, launching ‘AbbVie Race to Innovate’ at United States Grand Prix
- AbbVie signs with McLaren Mastercard F1 Team in first global sports sponsorship
- AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial
- /C O R R E C T I O N - AbbVie/
- AbbVie’s long-term Rinvoq data shows continued repigmentation in non-segmental vitiligo
- Lilly, Merck, AbbVie Stocks Surge. Why Healthcare Is Rallying Today.
- AbbVie, Eli Lilly among mega-cap healthcare stocks with A+ profitability grades
- AbbVie, Genmab score first-line DLBCL win for Epkinly, teeing up challenge to Roche's Polivy
- Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial
- AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeover
Headlines from the last 30 days, linking to the original publishers. See all market news →